Among patients with AAV who develop DAH, a subset also experience VTE, highlighting the complex care required to manage this population.
PackGene Biotech, Inc. announced today six presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting in Boston, May 11–15, highlighting the company's continued ...
VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, will participate in the Association for ...
Epicrispr Biotechnologies (“Epicrispr”), a clinical-stage company pioneering gene-modulating therapies, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of the ...
High-throughput virology, design of experiments, and small-molecule production enhancers optimize yield and increase ...
Please provide your email address to receive an email when new articles are posted on . A new simulation model can predict a range of clinical outcomes for various therapy strategies in patients with ...
U.S. Marines with 2nd Assault Amphibian Battalion (2d AABN), 2nd Marine Division (2d MARDIV), conduct an amphibious movement aboard an AAV-7A1 Assault Amphibious Vehicle during the unit's Marine Corps ...
AskBio founder R. Jude Samulski talks about the evolution and future of AAV gene therapy following his company’s blockbuster acquisition by Bayer in 2020. R. Jude Samulski, PhD It is rare that a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results